Teneliximab Explained

Teneliximab is a chimeric monoclonal antibody[1] binding to the immune stimulatory protein CD40.[2], it has not entered clinical trials.

Notes and References

  1. https://web.archive.org/web/20091016232326/http://whqlibdoc.who.int/druginfo/INN_2003_list49.pdf International Nonproprietary Names For Pharmaceutical Substances
  2. Book: Law CL, Grewal IS . Therapeutic Targets of the TNF Superfamily . Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges . Advances in Experimental Medicine and Biology . 647 . 8–36 . 2009 . 19760064 . 10.1007/978-0-387-89520-8_2 . Springer Science+Business Media . New York, N.Y. . 978-0-387-89520-8 . https://books.google.com/books?id=GMr1VYauOt0C&dq=Teneliximab&pg=PA24 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Teneliximab".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.